Drs. Jessie Seidelman and Dan Sexton, from both the DICON and DASON teams, worked on an editorial commentary on long-term oral therapy for treatment of bone and joint infections for the journal Clinical Infectious Diseases. The authors ask the questions: is oral therapy, given after initial surgical treatment (if indicated) and a few days of IV empirical or directed parenteral therapy, ready for “prime time?” In other words, are the findings in the original OVIVA noninferiority trial and the follow-up before-and-after efficacy trial reported by Warren et al of sufficient strength and validity to change practice? And if this is the case, what caveats and what exceptions to this new paradigm are important?
See commentary.